Hemispherx BioPharma, Inc (NYSE:HEB) released its earnings results on Monday. The specialty pharmaceutical company reported ($0.30) EPS for the quarter. During the same period last year, the company posted ($0.62) EPS.

Shares of Hemispherx BioPharma (NYSE:HEB) opened at 0.89 on Wednesday. Hemispherx BioPharma has a 12-month low of $0.72 and a 12-month high of $2.64. The company’s market capitalization is $18.46 million. The company has a 50 day moving average of $1.05 and a 200-day moving average of $1.42.

Earnings History for Hemispherx BioPharma (NYSE:HEB)

Hemispherx BioPharma Company Profile

Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.

5 Day Chart for NYSE:HEB

Receive News & Stock Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related stocks with our FREE daily email newsletter.